Publication: Omalizumab versus cyclosporin-A for the treatment of chronic spontaneous urticaria: can we define better-responding endotypes?
Loading...
Institution Authors
Author
Kocaturk E.
BÜLBÜL BAŞKAN E.
SU KÜÇÜK Ö.
Ozdemir M.
Ornek S.
Can P. K.
Hasal E.
ENGİN B.
Atakan N.
ALPSOY E.
Advisor
Program
Date
Language
Type
Publisher
Journal Title
Journal ISSN
Volume Title
Abstract
Background: Chronic Spontaneous Urticaria (CSU) is characterized by recurrent wheals and/or angioedema for longer than 6-weeks. Guidelines recommend Omalizumab (Oma) as first-line and Cyclosporine-A (Cs-A) as second-line treatment in antihistamine resistant CSU. This step-wise algorithm might be time-consuming and costly.
Description
Source
Keywords
Keywords
Tıp , Dahili Tıp Bilimleri , Dermatoloji , Sağlık Bilimleri , Medicine , Internal Medicine Sciences , Dermatology , Health Sciences , DERMATOLOJİ , Klinik Tıp , Klinik Tıp (MED) , DERMATOLOGY , CLINICAL MEDICINE , Clinical Medicine (MED) , Biomarker , Chronic urticaria , Cyclosporine , Omalizumab , BIOMARKERS
Citation
Kocaturk E., BÜLBÜL BAŞKAN E., SU KÜÇÜK Ö., Ozdemir M., Ornek S., Can P. K., Hasal E., ENGİN B., Atakan N., ALPSOY E., "Omalizumab versus cyclosporin-A for the treatment of chronic spontaneous urticaria: can we define better-responding endotypes?", ANAIS BRASILEIROS DE DERMATOLOGIA, cilt.97, sa.5, ss.592-600, 2022